Transcriptional control of the multi-drug transporter ABCB1 by transcription factor Sp3 in different human tissues by Gromnicova, Radka et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Transcriptional control of the multi-drug transporter
ABCB1 by transcription factor Sp3 in different human
tissues
Journal Item
How to cite:
Gromnicova, Radka; Romero, Ignacio A and Male, David (2012). Transcriptional control of the multi-drug
transporter ABCB1 by transcription factor Sp3 in different human tissues. PLoS ONE, 7(10), article no. e48189.
For guidance on citations see FAQs.
c© 2012 The Authors
Version: Accepted Manuscript
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1371/journal.pone.0048189
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
1 
 
 
 
 
Transcriptional Control of the Multi-drug Transporter ABCB1 by 
Transcription Factor Sp3 in Different Human Tissues 
 
Radka Gromnicova, Ignacio Romero and David Male 
Department of Life, Health and Chemical Sciences,  
The Open University, Milton Keynes, Bucks, UK. 
 
 
Address for Correspondence 
Professor David Male,   
Department of Life, Health and Chemical Sciences, 
The Open University,  
Milton Keynes, MK7 6AA, 
UK 
Tel. +44 1908659226;   
Fax. +441908654167; 
email: D.K.Male@Open.ac.uk 
2 
 
 
Abstract 
 
The ATP-binding cassette (ABC) transporter ABCB1, encoded by the multidrug resistance gene 
MDR1, is expressed on brain microvascular endothelium and several types of epithelium, but not on 
endothelia outside the CNS. It is an essential component of the blood-brain barrier. The aim of this 
study was to identify cell-specific controls on the transcription of MDR1 in human brain endothelium. 
Reporter assays identified a region of 500bp around the transcription start site that was optimally active 
in brain endothelium. Chromatin immunoprecipitation identified Sp3 and TFIID associated with this 
region and EMSA (electrophoretic mobility shift assays) confirmed that Sp3 binds preferentially to an 
Sp-target site (GC-box) on the MDR1 promoter in brain endothelium. This result contrasts with 
findings in other cell types and with the colon carcinoma line Caco-2, in which Sp1 preferentially 
associates with the MDR1 promoter.  Differences in MDR1 transcriptional control between brain 
endothelium and Caco-2 could not be explained by the relative abundance of Sp1:Sp3 nor by the ratio 
of Sp3 variants, because activating variants of Sp3 were present in both cell types. However 
differential binding of other transcription factors was also detected in two additional upstream regions 
of the MDR1 promoter.  Identification of cell-specific controls on the transcription of MDR1 indicates 
that it may be possible to modulate multi-drug resistance on tumours, while leaving the blood brain 
barrier intact. 
 
Keywords: blood-brain barrier, MDR1, p-gp1, Sp1, Caco-2. 
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Introduction 
 
Microvascular endothelium in the brain is a key component of the blood-brain barrier, which 
controls the movement of nutrients into the CNS and excludes many toxic molecules from the 
CNS.  Brain endothelial cells are connected by continuous tight junctions that confer low 
permeability to ions and hydrophilic molecules [1].  They also express several members of the 
ATP-binding cassette (ABC) super family, of which the most important is ABCB1, encoded 
by the multi-drug resistance gene, MDR1 [2,3].  (ABCB1 is often referred to as p-gp1.) 
Additional multi-drug resistance proteins (MRP) are located at the blood-brain barrier, 
including MRP-1, -2 and -4 (ABCC1, 2, 4) as well as breast-cancer resistance protein, 
(ABCG2) [4].  These features contribute to blood-brain barrier function and are responsible 
for maintaining brain homeostasis and normal neuronal activity. However, the multi-drug 
transporters also prevent the entry of many potentially useful drugs into the CNS.  
 
The multi-drug transporters are expressed in complex tissue-specific patterns. For example 
ABCB1 is expressed on brain endothelium, but not on endothelia that lack barrier properties. 
However, it is present on a variety of other cell-types, including intestinal epithelium and on 
cells from the proximal kidney tubules. Moreover ABCB1 is induced by a wide variety of 
drugs, and is present on many tumours, rendering these cell types resistant to treatment with 
some cytotoxic drugs. Hence, ABCB1 is subject to a variety of transcriptional controls, which 
affect both constitutive expression and induction in different cell types [5]. In order to 
selectively modulate ABCB1 expression in different cell types, it is essential to understand 
these cell-specific controls. The aim of this study was to identify transcription factors that 
control ABCB1 expression in human brain endothelium. 
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There have been many studies on the expression of ABCB1 in epithelial cells and tumours 
which have identified transcription factor binding sites in the proximal promoter of MDR1 
(Fig. 1). The MDR1 promoter lacks a TATA-box, but does have an inverted CCAAT sequence 
(Y-box).  Consequently, it has been proposed that transcription is initiated by NF-Y binding to 
the Y-box, rather than TFIID, which binds to TATA-boxes [6].  Furthermore, it has been 
shown that CCAAT-enhancer-binding protein-β (CEBP/β) and Specificity-protein-1 (Sp1), 
promote assembly of the RNA-polymerase II complex to the Y-box [7].  However, it is 
essential to note that these studies are based on tumours and epithelial cells. In contrast, there 
is little information on transcription control of MDR1 in brain endothelium. One study on rat 
brain endothelium has identified a distal promoter element ~10kb upstream of the transcription 
start site, which responds to steroids [8], but there is no data on the proximal promoter, which 
is expected to contain the key transcription factor target sites for gene expression. In this study 
we have analysed the proximal part of the MDR1 promoter up to 1kb upstream from the 
transcription start site (Fig. 1). 
 
Previous work from our laboratory has compared transcription factor profiles in endothelium 
from the brain and other tissues, with the aim of identifying distinctive sets of transcription 
factors which could induce or maintain the phenotype of barrier endothelium [9]. These 
studies identified a role for the Sp family, YY1 and TFIID in the regulation of the human 
transferrin receptor (TFR) promoter, leading to the proposal that Sp3 is required for TFR 
expression in brain endothelium. Subsequently, it was found that Sp3 is also involved in the 
control of occludin, a component of tight junctions [10].  This led us to the hypothesis that Sp3 
could be part of a more general system, controlling many proteins which are co-expressed in 
brain endothelium, but not other endothelia.  
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Four members of the Sp-family have been identified in brain endothelium, of which Sp3 and 
Sp1 are most abundant. Brain endothelium expresses particularly high levels of Sp3 in 
comparison with lung and dermal endothelium [9].  Sp1 is the prototype of a large family of 
transcription factors which bind GC-rich segments [11,12]. Sp1 itself is thought to be a 
constitutive factor that enhances the transcriptional initiation of numerous genes whereas Sp3 
has been reported to act as an activator or repressor depending on the cell type and conditions 
[13]. 
 
In view of our previous results on transcriptional control of TFR and occludin, this study 
focuses on the role of the Sp-family and other transcription factors, which have differential 
expression in brain and non-brain endothelium. Underlying this study is the objective of 
maintaining ABCB1 expression at the blood brain barrier, while modulating expression on 
tumours or other epithelial barriers. Hence the results with brain endothelium were compared 
with results from the well-studied epithelial colon carcinoma line, Caco-2. We also 
investigated the possible role of other transcription factors (CEBPβ, NF-Yα, PCAF, YB1 ) that 
have been reported to control MDR1 expression in epithelial cells or tumours.  
  
 
Results 
 
Expression of ABCB1 (p-gp1) in endothelial and epithelial cell lines 
The expression of ABCB1 was compared in the human cerebral microvascular endothelial cell line/D3 
(hCMEC/D3) and the epithelial tumour line Caco-2, by FACS (Fig. 2).  Both cell lines express 
ABCB1 over a wide range with similar median fluorescence.  In order to investigate how ABCB1 
expression is controlled in brain endothelium and to compare different cell types, promoter reporter 
vectors were generated containing segments of the proximal MDR1 promoter region (Fig. 1). This 
region was chosen because it contains a previously reported transcription start site active in epithelial 
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cells (+1), and the segment up to position +43 was required for full promoter activity [5]. The target 
sites of several transcription factors that are reported to be required for gene expression in epithelial 
cells or tumour cells are shown expanded on the region between -181 and -1bp (Fig. 1b).  
 
To identify active regions of the MDR1 promoter, five promoter-reporter vectors were transfected into 
hCMEC/D3 or Caco-2 cells and transcriptional activity determined by GFP expression (Fig. 3). The 
aim of the experiments was to detect whether the profile of activity of the reporter vectors was 
different in the two cell types, indicating that different sets of transcription factors were active on 
MDR1 in the two cells. All of the vectors showed some promoter activity compared to the empty 
reporter vector and analysis of variance (ANOVAR) on the data from each cell indicated that the 
vectors showed a pattern of differential activity (p<0.05 in both cases).  The region -457 to +43 was 
clearly most active in hCMEC/D3 cells, whereas the segment -338 to +43 was most active in Caco-2 
cells. The results indicated that different elements of the MDR1 promoter were required for optimal 
gene expression in the two cell types. 
 
For comparison, the vectors were also transfected into primary lung or myometrial microvascular 
endothelium. In these experiments the vectors E-A and F-A showed a low level of activity, and the 
other vectors were inactive (data not shown). However, the transfection efficiency in these 
experiments was low (5-10%) as determined using the CMV-promoter positive control vector. 
Therefore we cannot be certain that the low level of expression in non-brain endothelium is due to lack 
of appropriate transcription factors for MDR1.  It was not possible to carry out a comparison with 
primary brain endothelium due to the very limited amount of live human brain tissue available.  
 
Transcription factor binding to the MDR1 promoter 
To determine whether nuclear proteins from hCMEC/D3 cells bind to the MDR1 promoter, EMSA 
was carried out with a series of overlapping probes (Fig. 1a) to screen for transcription factor binding.  
The screen showed strong binding of nuclear proteins to probes C, E, F and G, with weaker bands 
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associated with probes H and K (screening data is not shown, but see Fig 4. and below). Hence, the 
data imply that the major protein interactions were with target sites in the regions -457 to -229 and -
161 to -40.   These regions lie within segment F-A [-457 to +42] that was most active in the reporter 
assays.  
 
Our earlier studies indicated that the transcription factors Sp3 and YY1 were critically important in 
controlling expression of TFR and occludin in brain endothelium. We therefore proposed that Sp3 
could be more generally used by brain endothelium to control tissue-specific gene expression. Two 
Sp-factor binding sites are located in the GC-rich box of MDR1 (Fig. 1b), however studies in 
epithelial cells and tumours indicated that it is Sp1 that targets this site [5, 6]. 
 
To investigate interaction of transcription factors with this region, EMSA was carried out using probe-
C [-181 to -1] and nuclear protein from hCMEC/D3 or Caco-2 (Fig. 4). The blots show 5 bands (a-e) 
with hCMEC/D3 nuclear proteins, and 4 bands (f-i) with Caco-2 nuclear protein. The transcription 
factors binding to region C were further analysed by blocking the EMSA with unlabelled 
oligonucleotides or supershifting with antibodies to transcription factors (Fig. 4). 
 
In brain endothelium, the results show that bands ‘a-d’ were blocked by a consensus Sp 
oligonucleotide with sequence homology to the GC-box. This indicates that bands ‘a-d’ are due to 
proteins binding to the GC-box. Furthermore, all of the bands were blocked by an AP2-consensus 
oligonucleotide which has two homology regions in probe-C, one corresponds with the GC-rich box, 
and the other lies at position [-64 to -89], between the AP1 site and the Y-box (Fig. 1). This pattern of 
blocking indicates that bands ‘a-d’ are due to proteins binding to the GC-rich box, and ‘e’ is binding to 
a region immediately upstream of the Y-box. Moreover, there was no blocking with consensus 
oligonucleotides corresponding to CEBP, NF1 and AP1 (data not shown), which confirms that the 
transcription factors were binding to the GC-box and not to the CEBP target, the Y-box or the AP1 
target region, respectively. Antibody to Sp3 removed bands ‘b’ and ‘d’ and substantially reduced the 
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strongest band ’c’, indicating that these bands are due to Sp3 binding. Antibodies to Sp1, TFIID and 
NF-Y had no effect (Fig. 4).  
 
In Caco-2 cells, band ‘f’ was blocked by an Sp consensus oligonucleotide and the AP2 consensus 
oligonucleotide. This band was supershifted by antibody to Sp1, implying that Sp1 is a component of 
this band.  Bands ‘g’ and ‘h’ were partly blocked by Sp and AP2 oligonucleotides and removed by 
antibody to Sp3, indicating that Sp3 targeting the Sp consensus sequence, is a component of these 
complexes. Band ‘i’ was removed by all treatments (both oligonucleotides and antibodies), which 
suggests a weak non-specific interaction with probe-C. 
 
These results implied that Sp3 associated with the GC-rich box in brain endothelium whereas Sp1 was 
associated with the promoter in Caco-2 cells. This result is in agreement with previous results on 
epithelial cells and tumours. We therefore investigated the relative expression and isoforms of Sp3 and 
Sp1 in brain endothelium. Immunofluorescence of hCMEC/D3 cells, primary brain endothelium and 
brain endothelium in situ, all show that Sp1 and Sp3 are both present in the endothelial line as well as 
primary brain endothelial cells  (Fig. 5). Previously we have found that both Sp1 and Sp3 can be 
detected in hCMEC/D3 by EMSA-supershift assay with a consensus Sp oligonucleotide probe. 
Moreover, the activity of Sp3 is higher in brain endothelium, than non-brain endothelium [9].  The 
different techniques, all indicate that Sp3 is strongly expressed in brain endothelium, although Sp1 is 
also present. 
 
To further investigate the relative importance of Sp1 and Sp3, chromatin immunoprecipitation (ChIP) 
was carried out using antibodies to a number of transcription factors and sheared chromatin from 
resting hCMEC/D3 cells. The precipitated DNA was detected by PCR using primers spanning the 
region D+C (see Fig.1). The results show that Sp3 is strongly associated with the proximal promoter in 
hCMEC/D3 cells but Sp1 was only weakly associated (Fig. 6a). Interestingly, TFIID associates with 
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the MDR1promoter in brain endothelium, even though it does not contain a TATA box. ChIP with 
antibodies to Pit-1, c-myb, GATA-2, YY-1 and Sp2 were all negative (data not shown).   
 
It was notable that the upper Sp3 band seen in EMSA with brain endothelium (Fig.4, band  ‘b’), was 
absent from the Caco-2 cells. We therefore investigated the possibility that Caco-2 cells lacked an Sp3 
isoform, which could explain the lack of Sp3 binding from these cells.  Sp3 is known to be produced 
in four principle variants, two of which (~117kDa) may be activating or suppressive depending on the 
gene and cell type whereas the two smaller bands  (~96kDa) are not activating [14].   To test this 
hypothesis, nuclear proteins from the two cell types were examined by Western blotting (Fig.6b).  The 
results show that both cells express all four variants of Sp3 (bands a,b,d,e). In addition some 
preparations of hCMEC/D3 cells expressed an additional band (‘c’) corresponding to a sumoylated 
form of the lower molecular weight variants [14]. Note that while it is valid to assess the relative 
amounts of the different isoforms of Sp1 or Sp3 in a single lane by this method, one cannot compare 
the amounts of Sp1 and Sp3, since the effectiveness of the anti-Sp1 and anti-Sp3 antibodies was 
different in Western blotting. 
 
Since two Sp3 bands appeared in EMSA with hCMEC/D3 nuclear protein and probe-C (Fig. 4), we 
hypothesised that these two bands corresponded to the two high molecular weight forms of Sp3, seen 
on the Western blots (Fig. 6b). To test this theory, we devised a novel two dimensional gel system 
with EMSA in the first dimension and SDS-PAGE in the second dimension. The resulting two 
dimensional gel was blotted and stained with anti-Sp3 in a Western blot. The results indicated that the 
two high molecular weight forms of Sp3 bound to the MDR1 promoter (probe-C) whereas the low 
molecular weight forms did not bind (data not shown).  This result was true for Sp3 (in nuclear 
protein) obtained from either hCMEC/D3 or Caco-2. 
 
Two previously reported isoforms of Sp1 (Fig. 6c, bands ‘f’ and ‘g’, 106kDa and 95kDa) were 
detected in both hCMEC/D3 and Caco2 cells. There was an additional smaller band (‘h’) in all of the 
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cells. Low molecular-weight proteins reacting with anti-Sp1 antibodies have been reported previously, 
but the relationship to full-length Sp1 has not been defined. It is known that Sp1 activity is controlled 
by proteolytic degradation, and it is therefore possible that band ‘h’ represents a degradation product 
caused by loss of the N-terminal activation domain. These data show that the selective binding of Sp3 
to the MDR1 promoter in brain endothelium is not related to the presence of activating or non-
activating isoforms of Sp3, or the absence of Sp1 isoforms in brain endothelium. 
 
The data suggested that activating variants of Sp3 bind to the MDR1 promoter in brain endothelium. 
Therefore, we would have liked to test whether removal of Sp3 results in a secondary reduction in 
ABCB1 expression. However, we have previously attempted to knockdown Sp3 with siRNA in 
hCMEC/D3 cells, and found that it resulted in cell death; this is not surprising in view of the large 
number of genes that have GC-rich boxes in their promoter and which require Sp-factors for their 
activation. We therefore tried an alternative method, using mithramycin which interferes with the 
binding of transcription factors to GC rich regions and might therefore be expected to reduce ABCB1 
expression [15].  hCMEC/D3 cells were cultured in 200nM mithramycin for 3 days and then analysed 
for ABCB1 expression by immunofluorescence and FACS. Contrary to the hypothesis, mithramycin-
treated cells had a significantly higher level of ABCB1 expression, than untreated cells (Mithramycin-
treated, 30.1 ± 1.88 : Control, 18.8 ± 0.97,  Mean of median fluorescence, n=3, p<0.01, by 
Student’s t-test). This result may be explained by the fact that mithramycin is itself a substrate of 
ABCB1, and cells that express low levels of ABCB1 are selectively inhibited in their growth/survival 
compared with high expressers,  an effect that has been previously shown with puromycin, another 
cytostatic ABCB1 substrate [16]. 
 
Since the differential binding of Sp3 to the GC-box is not explained simply by its incidence or variants 
within the cells, we compared the binding of transcription factors from the two cell types to upstream 
regions of the promoter by EMSA. The results showed differential protein binding to probes-E, -F, -J 
and -K (Fig.7). Regions E and F, which bind hCMEC/D3 transcription factors, are part of the active 
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promoter in these cells (Fig. 3).  Although there was only a low level of hCMEC/D3 nuclear-protein 
binding to probes J and K, there was one strong band from Caco-2 which bound to probe-J and three 
bands associated with probe-K.  Taken together the data suggest that Sp3 binds preferentially to the 
MDR1 promoter in brain endothelial cells, whereas Sp1 is more active in Caco-2 cells. However there 
is also differential transcription factor binding in the region -457 to -229 in hCMEC/D3 cells and at -
986 to -711 in Caco-2 cells, which may explain the different profiles of promoter activity seen in the 
two cell types. 
 
Discussion 
 
The data presented in this paper demonstrate that the transcription factor Sp3 associates with the GC-
rich box in the proximal MDR1 promoter in brain endothelium. In comparison, published work on 
other cell types has shown that it is Sp1 that drives MDR1 transcription [5]. Our experiments confirm 
the previous findings that Sp1 binds the MDR1 GC-rich box in Caco-2 cells, but indicate that MDR1 
is controlled differently in brain endothelium. Our previous work has shown that Sp3 is also required 
to control expression of occludin and TFR in brain endothelium [9,10]. Collectively, the studies 
suggest that a number of genes, characteristic of the blood-brain barrier phenotype use Sp3 for their 
transcriptional activation. 
 
The Western blots of Sp3 confirm previous findings of two long and two short forms of Sp3. The two 
long forms of Sp3 both contain two transcription-activation domains but the two short forms lack the 
second (3’) activation domain.  Production of the variants is complex, but in essence the two short 
forms are produced from transcript variants that lack exon-3, encoding the second activation domain 
[14,17].  Interestingly, the 2-dimensional gels indicated that only the long forms of Sp3 bound to the 
MDR1 promoter, even though all variants contain the DNA-binding zinc-fingers.  This suggests that 
other transcription factors interact with the long forms of Sp3 to promote DNA-binding. We have 
examined a number of cell types that either express or do not express ABCB1 (lung microvascular 
endothelium, MDR1-negative:  astrocytes, low expression : the kidney epithelial cell line ciPTEC 
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[18],  MDR1-positive); all of the cells have the high molecular weight forms of Sp3. Therefore the 
expression of MDR1 cannot be explained solely on the basis of selective expression of the high 
molecular weight, active forms of Sp3.  
 
The MDR1 gene lacks a TATA-box, but does have an invert CCAAT-box. It has therefore been 
assumed that assembly of RNA-polymerase would involve NF-Y (which binds to CCAAT) rather than 
TFIID (which binds to TATA) [7]. However it was notable that anti-NF-Y antibodies did not 
supershift the nuclear-protein complex binding to probe-C. It has also been proposed that CCAAT-
enhancer binding protein-β (CEBP/β), bound to its target (Fig. 1) would enhance the binding of NF-Y 
[5]. However, anti-CEBP/β antibody did not produce a supershift in the EMSA with probe-C, nor did 
a CEBP-oligonucleotide block the nuclear-protein complexes. Moreover, the oligonucleotide-blocking 
assays with the Sp consensus sequences showed that the major nuclear protein complex was bound to 
the GC-box with a minor element upstream of the CCAAT-box. In short, there was absolutely no 
evidence for transcription factor binding to the CCAAT-box or a function for CEBP/β in human brain 
endothelial cells. In contrast, TFIID was detected in association with the promoter in ChIP (Fig. 6a).  
Since there is no target site for TFIID in that segment, it suggests that it is not directly bound to the 
promoter but is associated with it, by interaction with another transcription factor. In this context, it 
has been shown that the second activation domain of Sp3 (encoded by exon-3) can bind to TFIID, and 
recruit it to TATA-less promoters [11].  
 
The question arises of why Sp3 should bind to the MDR1 promoter, rather than Sp1?  It has been 
proposed that Sp3 will compete efficiently with Sp1 on promoters that contain multiple Sp target sites 
clustered within the proximal promoter [19]. It is notable therefore that the MDR1 promoter contains 
two closely linked Sp target sites and hence is a candidate gene for control by Sp3. How it is 
controlled in different cells will depend on the variants of Sp3 that are expressed, and on other 
transcription factors that interact with Sp3. 
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Interestingly, we sometimes noted an Sp3 band in the hCMEC/D3 cells (Fig. 6b, band ‘c’) 
corresponding to the sumoylated form of the shorter variants; there was no evidence for the 
sumoylated form of the long isoforms (127kDa).  This indicates a possible mechanism for increasing 
MDR1 transcription in these cells, ie destruction of the inhibitory form of the transcription factor Sp3.  
The complex pattern of Sp3 variants seen in different cell types may help to explain, how Sp3 can act 
as an activator on some genes/cells, but a repressor on others. 
 
The data indicate that additional tissue-specific controls affect MDR1 transcription, ie Sp3 is 
necessary but not sufficient for MDR1 expression in brain endothelium whereas Sp1 is preferentially 
used in Caco-2 cells. Additional transcriptional controls may lie in regions E and F (hCMEC/D3) and 
in regions E, J and K (Caco-2) since there is differential binding of transcription factors to these 
segments (Fig. 7).  However we were unable to identify the transcription factors using the panel of 
supershift antibodies listed in table 1, which includes all the transcription factors previously identified 
as acting on MDR1 in other cell types. 
 
 In previous studies, we have shown that the presence or absence of YY1 was correlated with the 
on/off state of occludin and the transferrin receptor in endothelial cells from different tissues [10].  We 
could not however detect YY1 bound to the region of the MDR1 promoter analysed here – ie up to 
1kbase upstream of the transcription start.  The absence of YY1-binding indicates that it is not 
required for the expression of MDR1 in brain endothelium, although it could still have a role in 
preventing transcription in non-brain endothelia. 
 
It is possible that there are additional sites controlling MDR1 expression that are more distant from the 
transcription start-site, and it has previously been shown that a site 10kbases upstream is responsive to 
steroids, via activation of the pregnane-X receptor [8], although expression of this receptor is reported 
to be very low on hCMEC/D3 cells [20]. However, transcriptional activators usually bind within 1-2kb 
of the transcription start site, and the reporter data presented here (Fig. 3) indicates that this is also true 
for MDR1 in brain endothelium. 
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In summary, the data supports the proposal that Sp3 is required for activation of MDR1 in brain 
endothelium, whereas the cell types examined previously use Sp1 to activate MDR1. Sp3 may recruit 
TFIID to the MDR1 promoter by binding to the second activation domain of Sp3, although TFIID 
does not itself bind directly to the gene. Additional transcription factors acting upstream of the GC-
box in the region E-F (Fig.1) are differentially active in brain endothelium and are required for optimal 
transcription in these cells. 
 
The identification of cell-type specific controls on ABCB1 expression is important, because it 
indicates that it may be possible to maintain ABCB1 expression on brain endothelium, while reducing 
it on other cell types [21],  for example in tumour therapy. Conversely, if one wanted to reduce 
ABCB1 expression on brain endothelium, it could be done without removing its protective function 
from other cell types. 
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Material and Methods 
 
Cell cultures 
The human brain microvascular endothelial cell line,  hCMEC3/D3 [22], was grown on 
collagen-coated plates in EGM-2 MV medium supplemented with 2.5% foetal bovine serum, 
hydrocortisone, VEGF, epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), 
human fibroblast growth factor (FGF), ascorbic acid, gentamicin sulphate and amphotericin-
B. hCMEC/D3 cells were used at passage 21-30.  Primary human brain microvessel 
endothelium was obtained from surgical resection, undertaken to treat epilepsy, with the 
informed consent of the patient. The cells were isolated from a small area of unaffected tissue 
at the tip of the temporal lobe, by collagenase/dispase digestion and isolation on BSA and 
percoll gradients as previously described [23]. 
The human colon-derived epithelial cell line Caco-2 [24] was maintained in monolayer 
cultures in MEM with 10% foetal bovine serum, penicillin and streptomycin. 
 
Flow cytometry, Immunofluorescence and Immunohistochemistry 
hCMEC/D3 and Caco-2 cells were analysed for expression of ABCB1 by flow cytometry. Cells were 
washed in HBSS without Ca++/Mg++, detached from the flasks with trypsin/EDTA, and fixed with 2% 
paraformaldehyde in PBS for 30m. The cells were washed, resuspended in 5g/l BSA in PBS and 2x105 
cells were stained with mouse IgG2a antibody to ABCB1 (p-gp1, Clone MRK16, Kamiya Biomedical) 
at a final concentration of 15μg/ml in 50μl for 2h. The secondary antibody was 1/100 rabbit anti-
mouse-FITC (Sigma) for 1h. Cells were washed twice with PBS between the antibody incubations and 
before FACS analysis.  
For  detection of transcription factors in vitro by immunofluorescence, endothelial cells were grown to 
confluence on collagen coated coverslips before fixation with 4% paraformaldehyde and staining, with 
20μg/ml antibody to Sp1 or Sp3, followed by 1/100 FITC-labelled anti-mouse-IgG as previously 
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described [9]. Immunohistochemistry for Sp3 and Sp1 was carried out on cryostat sections of the 
unaffected putamen from an individual with multiple sclerosis [25] using primary antibodies to Sp1 
and Sp3 (see table 1) at 10μg/ml.  In all immunofluorescence and immunocytochemistry experiments, 
isotype-matched primary antibodies at equivalent dilution to the test antibody were used for the 
negative controls. 
 
Promoter-vectors, transfection and FACS analysis 
The MDR1 promoter segments were prepared by PCR, using primers corresponding to positions in the 
MDR1 promoter indicated in Table 2 and as a template, a vector containing the full MDR1 promoter 
region, kindly supplied by Professor Mike Waring (University of Cambridge). The amplified segments 
were cloned into pGlowTOPO (Invitrogen) and the sequences of the gene segments and their correct 
orientation, upstream of the GFP-reporter gene was checked by PCR before use in transfection assays. 
pGLOW containing a strong CMV-promoter was used as positive control and to check transfection 
efficiency. Empty, closed vector was used as a negative control to determine background fluorescence. 
 
hCMEC/D3 cells were plated at  2-6 x 105 cells  per well on 6 well plates in 2 ml of EGM2-MV 
medium without antibiotics but supplemented with serum and growth factors and cultured until 60% 
confluent. For each transfection, 2µg of DNA was diluted in 250µl of OptiMEM® medium and 10µl of 
Lipofectamine™ 2000 was diluted in 250µl OptiMEM® Medium. DNA-Lipofectamine™ 2000 
complexes were produced according to the manufacturer’s protocol (Invitrogen) and 500µl was added 
directly to each well and incubated at 37°C for 12h. The complexes were then removed from the wells 
and EGM2-MV medium without antibiotics but with reduced serum (1%) and growth factors was 
added and cells cultured for a further 72h before analysis of reporter GFP expression.  In these 
conditions transfection efficiency of hCMEC/D3 cells was 40-60% as distinguished by increased 
size/granularity  [10]. Caco-2 cells were transfected under similar conditions, for 6 hours before 
removal of the complexes, and were then maintained in MEM with 10% FCS, for 54h before assay 
(transfection efficiency 30-45%). Transfected cell monolayers were washed in HBSS, detached with 
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0.25% Trypsin-EDTA, centrifuged at 300g for 5 min and resuspended in HBSS without phenol-red 
and were then analysed immediately by FACS. In the FACS analysis, the transfected cells were gated 
by their forward-scatter and side-scatter, and the median fluorescence of 10,000  transfected cells was 
determined  ie. non-transfected cells were not included in the analysis. Specific fluorescence is defined 
as the median fluorescence of cells transfected with a reporter vector minus the median fluorescence of 
cells transfected with the empty vector. Results are shown as the mean ±SEM of the specific 
fluorescence from 3 independent determinations. 
 
Chromatin Immunoprecipitation (ChIP) assays 
Chromatin was prepared as described previously [10] and fragmented using an enzymatic shearing 
cocktail to generate DNA fragments of 1-2kb in length. Two large flasks, containing ~9×106 resting 
hCMEC/D3 cells were used for each chromatin preparation to produce 2ml of sheared chromatin, 
sufficient for eight immunoprecipitations. 
 
The immunoprecipitation stages were based on a kit supplied by Upstate. Each 250µl sheared 
chromatin lysate was pre-cleared with 40µl of salmon sperm DNA (GibcoBRL) /Protein-A Agarose-
50% slurry for 1 h at 4°C. The cleared sample was then incubated overnight at 4ºC with 2μg antibody 
specific for Sp1, Sp3, TFIID, YY1, Pit-1, c-myb or GATA-2  (Santa Cruz, Biotechnology). 60 μl of 
salmon sperm DNA/Protein-A Agarose slurry was then added and further incubated for 1h at 4ºC with 
rotation. The protein-A agarose /antibody/chromatin complex was pelleted and washed successively 
with low-salt buffer, high-salt buffer, LiCl complex wash buffer and Tris/EDTA.  The bound 
chromatin was then eluted by two 15 min incubations in 250μl 1% SDS, 0.1M NaHCO3 and the two 
eluates were pooled.  
The protein-DNA cross-links were reversed, by adding 20μl of 5M NaCl to each eluate and heating at 
65ºC for 4h. Then, 10μl of 0.5M EDTA, 20μl 1M Tris-HCl, pH 6.5 and 2μl of 10mg/ml Proteinase K 
was added and incubated for 1h at 45ºC. After addition of 3µl glycogen (2 µg/µl), DNA was recovered 
by phenol/chloroform extraction and ethanol precipitation and redissolved in Tris/EDTA, pH 8.4 for 
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use in PCR analyses. PCR for ChIP assays used primers spanning the segment DC (see Fig. 1), 
annealing at 50ºC for 30s, with an extension time of 60s at 74ºC and 35 cycles of amplification. The 
amplified segments were analysed using 2% agarose gels in TAE buffer. 
 
Electrophoretic mobility shift assays (EMSAs) 
Nuclear protein extracts were isolated from cells as previously described, diluted to 2-5mg/ml and 
stored at -80ºC before use [10].  Biotinylated  EMSA probes, corresponding to MDR1 promoter 
fragments (Table 2, Fig. 1a) of  <200bp, were prepared by PCR  from the full length MDR1 promoter 
template using one conventional oligonucleotide primer and one biotinylated primer. The PCR 
products were run on 2% agarose gels and fragments migrating at the appropriate size were excised 
from the gel, extracted and purified (SpinPrep Gel DNA kit, Novagen).  Probes were diluted to 1-
2ng/μl for use in the assay. 
The EMSA was based on a kit from Pierce (LightShift Chemiluminescent EMSA). Briefly, 1-2ng of 
biotinylated EMSA probe was incubated for 20 min with 10μg of nuclear protein extracts in a final 
volume of 20μl binding buffer which included MgCl2, NP40, and poly dIdC at the manufacturer’s 
recommended concentrations. In some cases the nuclear proteins were pre-incubated for 20 min with  
0.4 μg oligonucleotides (cold blocking assay) or with 1-3μg antibody against specific transcription 
factors (supershift assay). Details of the blocking oligonucleotides are given in Table 3 and supershift 
antibodies are described in Table 2. 
The electrophoretic mobility shift assays were then conducted on 6% polyacrylamide gels in 0.5x 
TBE. The gel was prerun at 80V for 60 min. The samples were then loaded and electrophoresed at 
90V for 70 min, at which time the free probes were near the bottom of the gel. The complexes were 
transferred by wet blotting (in 0.5x TBE) onto nylon membrane (Amersham Hybond N+) at 100 V for 
1h. The nucleic acids were immobilised on the blots by UV-crosslinking (120mJ/cm2) and the position 
of the biotinylated probes identified by incubation with streptavidin-horseradish peroxidase, and 
chemiluminescent detection according to the manufacturer’s protocol.  
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Western Blotting 
 
Nuclear protein samples were prepared in non-reducing or reducing conditions and separated in 6% 
SDS-polyacrylamide gels. The proteins were transferred onto nitrocellulose membranes which were 
blocked with 5% non-fat milk in PBS containing 0.05% Tween-20 at 4 °C overnight. Immunoblotting 
was performed using anti-Sp3 or anti-Sp1 (200ng/ml) (Santa Cruz Biotechnology) as primary 
antibodies, for 1h at room temperature. Membranes were then washed five times in PBS containing 
0.05% Tween-20 and incubated with secondary antibody goat anti-rabbit IgG conjugated to HRP (1 : 
5000) (Invitrogen) for 1h at room temperature. Immunoblots were washed five times in PBS/Tween-
20 and once in PBS only. The enhanced chemiluminescence detection system (Amersham) was used 
for visualization.    
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Legends 
 
 
Figure 1 Diagram of the human MDR1 proximal promoter.   
(A) The promoter of MDR1 from -1000bp to +100bp is illustrated diagrammatically. Numbering is 
based on the proposed transcription-start site at +1 (arrow). Two regions of high inter-species 
homology are indicated by grey bars. The positions of nine overlapping probes (A,C,D,E,F,G,H,J,K) 
used in EMSA are indicated above the main scale. 
(B) The segment corresponding to probe C is expanded below, to show potential target sites of 
transcription-factors in epithelial cells and tumours, as well as a Y-box and a GC-rich box. 
CAAT/EBP  = CAAT enhancer binding protein; AP1 = Activating protein-1. 
 
Figure 2 Expression of ABCB1 on hCMEC/D3 and Caco-2. 
Representative FACS plots of ABCB1 expression on hCMEC/D3 and Caco-2 cells. The filled 
histograms are from immunofluorescence staining with a primary antibody to ABCB1 (MRK16) and 
open histograms are with an isotype-matched negative control as primary antibody. The figures show 
the mean (± SEM) of the median fluorescence of four independent experiments with each cell-type. 
(The secondary antibody, the staining procedure and FACS acquisition parameters were identical in all 
experiments.) 
 
Figure 3 Activity of MDR1 promoter gene segments. 
Specific activity of five MDR1 promoter-reporter vectors was measured in hCMEC/D3 and Caco-2 
cells by FACS. The promoter segments correspond to the regions shown in figure 1. D-A = -228 to 
+43: E--A = -338 to +43: F---A = -458 to +43: G----A = -617 to +43: K-------A = -986 to +43. The 
data shows mean ± SEM of the median fluorescence, minus background from 3 independent 
determinations.  
 
Figure 4 Interaction of Sp transcription factors with the MDR1 promoter. 
(A) EMSA with probe-C in lanes 1-9, and hCMEC/D3 nuclear protein in lanes 2-9. Protein-
binding was blocked with a consensus Sp oligonucleotide, a mutated Sp oligonucleotide (Sp-
mut.) and a consensus AP2 oligonuceotide (lanes 3-5). Supershifts were attempted with 
antibodies to Sp3, Sp1, TFIID and NFY (lanes 6-9). The nuclear protein produced five shifted 
bands, of which three (b,c,d) were reduced by anti-Sp3. 
(B) EMSA with probe-C in lanes 1-7 and Caco-2 nuclear protein in lanes 2-7. The nuclear 
proteins produced 4 major shifted bands (f-i). Protein-binding was blocked with consensus 
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oligonucleotides for Sp or AP2 (lanes 3 & 4). Supershifts with specific antibodies (lanes 5-7) 
indicated that band ‘f’ was produced by Sp1,  bands ‘g’ and ‘h’ by Sp3. Band ‘i’ was 
substantially reduced by all treatments. 
 
Figure 5 Expression of Sp1 and Sp3 in human brain endothelium in vitro and in situ. 
Expression of Sp1 and Sp3 by immunofluorescence in hCMEC/D3 cells and primary human brain 
endothelium and by immunohistochemistry in blood vessels in the putamen of human brain. 
 
Figure 6 Trancription factor binding to the MDR1 promoter in brain endothelium. 
(A) ChIP was performed on hCMEC/D3 cells with antibodies to TFIID, Sp3, Sp1 and a control IgG. 
The proximal MDR1 promoter was detected by PCR, with primers spanning the region -223 to -1 (see 
figure 1). Full length promoter was used as a positive control (Pos.) No chromatin was used as an 
additional negative control (Neg.). 
(B) Western blotting of nuclear proteins from hCMEC/D3,(D3) or Caco-2 cells, with antibody to Sp3. 
Bands ‘a’ and ‘b’ correspond to the activating/suppressive variants of Sp3. Bands ‘d’ and ‘e’ 
correspond to non-activating variants. 
(C) Western blotting of nuclear proteins from hCMEC/D3 (D3), or Caco-2 cells, with antibody to Sp1. 
Previously reported variants of Sp1 correspond to bands ‘f’ and ‘g’. The blot was stripped and 
reprobed with antibody to TFIID as a positive control for loading and transfer. 
 
Figure 7 Differential binding of transcription factors to the MDR1 promoter in brain 
endothelium and Caco-2. 
EMSA with probes E, F, J and K and nuclear proteins from hCMEC/D3 (D3) compared with Caco2. 
Arrows indicate bands that are strongly expressed in the Caco-2 cells, but absent or at low levels in 
hCMEC/D3 cells. 
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Table 1  Primary antibodies used in ChIP, EMSA, Western blotting and immunofluorescence 
 
Specificity Speciesa Source Clone/Serum  Useb 
Sp 1 (PEP 2) Rabbit  Santa Cruz  Bio. Sc-59 ChiP  WB  IF 
IHC 
Sp 1 (IC6)  Mouse  Santa Cruz Bio. Sc-420  EMSA 
Sp 3 (D-20) Rabbit  Santa Cruz Bio. Sc-644 ChIP WB IF 
EMSA IHC 
TFIID (TBP) (SI-1)  Rabbit  Santa Cruz Bio. Sc-273  ChIP WB  
TFIID (TBP) (N-12) Rabbit  Santa Cruz Bio. Sc-204 EMSA 
NFY-A Rabbit  Novus Biol. NBP1-67884 EMSA 
YB1 Rabbit  Novus Biol. NBP1-40492 EMSA 
CEBP β Rabbit  Novus Biol. NB100-91681 EMSA 
PCAF Rabbit  
 
Sdix 3459.00.02 EMSA 
NFY Rabbit  AbD Serotec AHP298 EMSA 
Pit-1 Goat Santa Cruz Bio. Sc-16288 ChIP 
GATA-2 (CG2-96) Mouse  Santa Cruz Bio. Sc-267 ChIP EMSA 
c-Myb Rabbit Santa Cruz Bio Sc-7874 ChIP EMSA 
 
P-gp1 Mouse Kamiya Biomed. MRK-16 IF  FACS 
 
a. Rabbit and goat antibodies are polyclonal. Mouse antibodies are monoclonal. All antibodies were 
affinity purified.  
b. Antibodies were used for Chromatin immunoprecipitation (ChIP), Western blotting (WB, [200-
500ng/ml]), Immunofluorescence (IF, [10-20μg/ml]), electrophoretic mobility shift assays (EMSA, 
[20-100μg/ml]) or immunohistochemistry (IHC) (10μg/ml).  
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Table 2  Sequences of probes in MDR1 promoter region 
 
Probe Position in  NT007933.15* Size (bp) 
A 25263083 - 25263002 82 
C 25263224 - 25263044 181 
D 25263272 - 25263204 69 
E 25263382 - 25263252 131 
F 25263500 - 25253361 140 
G 25263664 - 25263478 187 
H 25263775 - 25263645 131 
J 25263887 - 25263755 133 
K 25264029 - 25263866 164 
 
* Homo sapiens, chromosome-7  genomic contig. Reference sequence 
26 
 
 
 
Table 3 Consensus dsDNA blocking oligonucleotides 
Target  Sequence of consensus oligonucleotide 
Sp 5'-ATTCGATCGGGGCGGGGCGAGC-3' 
Sp mutant  5'-ATTCGATCGGTTCGGGGCGAGC-3'
AP1 5’-CGCTTGATGAGTCAGCCGGAA-3’ 
AP2 5´-GATCGAACTGACCGCCCGCGGCCCGT-3´
c/EBP 5’-TGCAGATTGCGCAATCTGCA-3’
TFIID 5’-GCAGAGCATATAAAATGAGGTAGGA-3’ 
YY1 5’-CGCTCCCCGGCCATCTTGGCGGCTGGT-3’
c-Myb 5'-TACAGGCATAACGGTTCCGTAGTGA-3'
GATA  5'-CACTTGATAACAGAAAGTGATAACTCT-3'
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Figure 5 Expression of Sp1 and Sp3 in brain endothelium in vitro and in vivo
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Figure 7  Differential transcription factor binding to the MDR1 promoter
‐ D
3
C
a
c
o
2
‐ D
3
C
a
c
o
2
‐ D
3
 
C
a
c
o
2
‐ D
3
C
a
c
o
2
Probe‐E                 Probe‐F                Probe‐J               Probe‐K   
